What is the best way to establish a business presence in Australia?
As a foreign company, there are a number of ways you can enter the Australian market. While it is recommended that you consider all avenues, two of the most common options include:
01. Establishing or acquiring a subsidiary company in Australia (Proprietary Company)
02. Establishing an Australian branch by registering a company with ASIC (Registered Foreign Company)
Before deciding which route to take, speak with ABA Bioscience Consulting to learn more about the advantages and disadvantages of each, as well as implications to be aware of.
If a foreign company establishes a business within Australia to manage their domestic operations, this is known as a Proprietary Limited Company (Pty Ltd). This means that they can operate as any other Australian Pty Ltd company.
The greatest advantage of a Pty Ltd is that other Australian entities often prefer interacting with Pty Ltd’s over Registered Foreign Companies.
To incorporate a Proprietary Company, there are 2 key steps you must take.
01. Choose a name for your company
When choosing your company name, you must first ensure your preferred name has not already been taken. This can be done by completing a name search through the corporate regulator, ASIC – ABA Bioscience Consulting will do this for you.
02. Apply for registration as an Australian company.
ABA Bioscience will request required information from you, including but not limited to the below:
Post-incorporation, there are a number of additional tasks to be completed. These include:
Please note that the tasks listed above are general, minimum requirements. ABA Bioscience Consulting will work with you in relation to other relevant items depending on your circumstances.
An Australian Business Number (ABN) is a unique identifying number for business names and companies and is also used for a range of tax and other business purposes.
Your ABN is issued by the Australian Business Register and generally includes your ACN with a two-digit prefix.
Using your ABN, you will be able to:
An Australian Company Number (ACN) is a unique identifying number issued upon registration of your company. This number must be displayed on all company documents and can be obtained through ASIC.
A Tax File Number (TFN) is a unique identifying number issued by the Australian Taxation Office and is an important element of starting a business. This is because any business that trades (or intends to trade) will need a TFN
We will obtain your Tax File Number (TFN) when applying for your Australian Business Number (ABN) through the Australian Business Register.
As an Australian company, you are required to maintain financial records and registers of both financial and administrative transactions.
Depending on the size of your company, you may also be required to create financial reports on an annual basis.
Even if your company is owned in entirety by foreign subsidiaries, you will still be expected to meet these requirements unless otherwise specified by ASIC.
You also have an obligation to notify ASIC of any changes to the following:
Please note that the list is general. ABA Bioscience Consulting will work with you to ensure all your reporting requirements are met.
ABA Bioscience Consulting specialise in assisting offshore companies to establish a business presence in Australia. We work with you to remove the complexities of navigating a new jurisdiction so you can focus on what matters most.
We have established an efficient process that ensures your Australian entity will be fully operational within a number of weeks from providing us with all required information. See Your Journey for more information.
What are the advantages of establishing a Registered Foreign Company?
For foreign companies that would prefer not to incorporate a separate Australian entity, a Registered Foreign Company is usually the best option. This is because it is not a separate legal entity from the parent company and it operates like another ‘branch’ of the company in Australia.
The Research and Development (R&D) Tax Incentive is an Australian Government initiative supporting Australian based businesses to create or develop new or improved products, systems and original solutions.
R&D helps to boost competitiveness and improve productivity across the Australian economy, while the R&D Tax Incentive provides a targeted tax offset to encourage companies to engage in R&D in Australia.
There are 2 tiers of benefit for the R&D Tax Incentive.
To be eligible for the 43.5% refundable tax offset, your company group must have an annual aggregated turnover of less than $20 million AUD and an annual R&D expenditure of at least $20,000 AUD.
If your company group has an annual aggregated turnover of more than $20 million AUD and annual R&D expenditure of at least $20,000 AUD, you may be eligible for the 38.5% non-refundable tax offset, rather than the cash refund.
To be eligible for either tier, your company must also be either:
Aggregated group turnover is the total annual turnover of the Australian subsidiary, any entity connected with the R&D entity in Australia or overseas and any affiliated entity in Australia or overseas.
It should be noted that any dealings between these entities will be excluded. Annual turnover is the sum of ordinary income generated in the ordinary course of business activities throughout the year, inclusive of sales and license fee revenue but exclusive of capital raised.
Entities are considered to be grouped in either of the following circumstances:
An entity is said to control another if either of the following conditions applies to the entity, its affiliates or both:
Yes. Eligible R&D activities must be registered with AusIndustry within 10 months of the end of financial year in which they were undertaken in order to claim the R&D Tax Incentive benefit on eligible R&D expenditure.
The team at ABA Bioscience Consulting are specialists in this field and can work with you to identify eligible activities and relevant expenditure that can be included in your R&D Tax claim.
Legislative criteria stipulate a minimum annual spend of $20,000 on eligible R&D expenditure in order to claim the R&D Tax Incentive.
The maximum claimable amount is $100 million AUD of eligible R&D expenditure per annum for an R&D entity.
Yes, although to claim expenditure on R&D activities conducted outside Australia you must first obtain a ruling called an Advanced/Overseas Finding.
The process of obtaining an overseas finding is quite tedious and lengthy however absolutely worthwhile when there are activities of significant value conducted outside of Australia. These activities must have a direct scientific link to eligible Australian research and clinical trial activities (core R&D activities) and cannot be undertaken in Australia for reasons such as legislation, lack of Australian capability, or lack of access to a population of living things. This process could be applied to some preclinical work, such as toxicology studies, drug formulation activities or even some clinical studies conducted in parallel with Australian research studies.
There are several conditions that must be met in order for a successful ruling to be awarded, allowing your activities conducted outside Australia to be claimed under the R&D Tax Incentive.
01. The activities must be covered by an advance/overseas finding stating that the activities are eligible.
02. The activities must have a significant scientific link to one or more ‘Australian core activities’ registered or reasonably likely to be conducted and registered.
03. The activities must be unable to be conducted within Australia because of one or more of the reasons listed below:
Expenditure on activities conducted overseas must not exceed expenditure on certain Australian activities.
If your company has a tax loss at the end of the income year, no tax is payable. Instead, your losses will be carried forward into future years to offset against your future profits. When your losses have been absorbed by your profits, you will then be required to pay tax.
By claiming the R&D Tax Incentive, you can essentially cash out your losses at a rate of 43.5% of eligible R&D expenditure instead of carrying them forward.
The amount you will be eligible to receive as a cash refund depends on the amount of R&D expenditure your business has and the magnitude of the losses; tax losses must be equal to or greater than R&D expenditure to claim the full 43.5%.
If your R&D expenditure is large and you make a small profit, you will still be able to claim a sizeable refund.
The subsidiary must be financed through either loans or capital. While capital is favoured, neither avenue is classified as taxable income.
Essentially, the parent funds the R&D activities in Australia by way of loans or capital. If the R&D expenditure is deductible under the R&D Tax Incentive scheme, but there is no income to offset the expenses, a tax loss will be generated in the Australian entity.
To start with, the overseas parent can fund R&D expenses on behalf of the subsidiary. However, the Australian subsidiary is required to incur the expenditure and reimburse/pay the parent for these expenses (by way of cash transaction or constructive payment) prior to the end of the claim year to receive the R&D tax benefit on that expenditure.
If this payment is not processed in the year of the R&D claim, the additional R&D benefit is not available until the income year in which the payment is made.
Yes. Intellectual property may be owned by an overseas company while still being eligible for the R&D Tax Incentive.
In this instance, it’s even more important for the company applying for the R&D Tax Incentive to be aware of international tax obligations and transfer pricing issues.
This is a complicated facet of the R&D Tax Incentive so it is recommended that you discuss this further with ABA Bioscience Consulting.
To be eligible under the R&D Tax Incentive scheme, expenditure must be spent on eligible R&D activities. Some of the most common eligible R&D expenses include things like research materials, drug products, TGA fees, project management, investigator and site payments and specific insurance costs.
Get in touch with ABA Bioscience Consulting to learn more about the specific claimable expenses relevant to your research.
If your company has an aggregated turnover of less than $20 million, you may be able to transfer the 43.5% tax benefit into a cash rebate. This is particularly beneficial for companies experiencing significant tax losses in Australia as it provides a significant cash flow advantage in order to fund future R&D activities.
According to Section 201B of the Corporations Act 2001, a director can be any individual who:
This includes foreigners, so long as they meet the above requirements.
No, all Proprietary Limited companies are required to have at least one director who primarily resides in Australia.
This is dependent on a number of factors. For good corporate governance, it is strongly recommended that meetings are held to make decisions. These can be held in person, over the phone or virtually. Decisions can also be made through flying or circular minutes. ABA Bioscience Consulting can assist you by managing all of these processes.
When providing your consent of appointment as a director, you will be required to supply a number of things, including:
A constitution is a contract that defines the rules that determine the relationship between and activities of a company, its directors and its shareholders. The constitution usually offers direction on a range of procedural governance matters.
ASIC defines a constitution as being a contract between:
A constitution is required for the following companies:
If a company is not governed by a constitution, it will then be subject to the replaceable rules - basic rules defined in the Corporations Act 2001.
ABA Bioscience Consulting will provide you with appropriate advice. Typically, we recommend companies have a constitution rather than rely on the replaceable rules.
The replaceable rules are basic rules for governing a company and are defined in the Corporations Act 2001. The replaceable rules can be used in instances where the company chooses not to adopt a constitution.
In cases where a company’s sole director and shareholder are the same person, the replaceable rules do not apply.
As such, ABA Bioscience Consulting typically recommends the adoption of an appropriate constitution rather than relying on the replaceable rules.
Yes. As outlined in The Corporations Act 2001, share ownership is not restricted to Australians. With this in mind, it is recommended that foreign shareholders understand Australian laws in relation to share ownership and have a thorough understanding of the tax and legal implications in their resident country. Get in touch with our team to learn more about how we can help you satisfy all tax and legal implications.
As stipulated under Section 252 of the Income Tax Assessment Act 1936, a Public Officer is a representative of your company who deals directly with the Australian Taxation Office and other government departments regarding company affairs. This can include things like submitting company income tax returns and keeping records.
To be a Public Officer, an individual must satisfy the following criteria:
As stipulated in the above criteria, a Public Officer must ordinarily reside in Australia. Therefore, a foreigner is not eligible to be a company’s Public Officer.
To appoint a Public Officer, the company’s board will generally pass a resolution. The nominated Public Officer will then need to sign a form consenting to their appointment. After consent has been formalised, the company must inform the Australian Taxation Office of the appointment in writing.
A Corporate Key is an identifying number that is unique to your ACN. Similar to a PIN number, your Corporate Key should be considered highly confidential as it enables access to your private company information. For this reason, it is important that a Corporate Key is never displayed or disclosed publicly.
This is dependent on the unique circumstances of each company. Working with ABA Bioscience Consulting, we can help you to understand the considerations associated with shares.
A registered office is the official address of a company where all communications from the Australian Taxation Office, ASIC and other governing bodies will be sent. For this reason, all companies must have a registered office.
Unlike a principal place of business, a registered office may be separate from the place where your business operates, for instance, the office of a company representative or ABA Bioscience Consulting.
The principal place of business is the location where your business trades or operates. It is usually the location where communications from customers and suppliers are sent.
A principal place of business can be the same as your registered office, but this is not a requirement.
Manager
Manager
Alex is the ABA Bioscience Team’s specialist Research and Development Consultant. He spends his days meticulously drafting and preparing R&D Tax Incentive narratives to ensure that our clients’ activities and supporting information are displayed in line with current legislative requirements to mitigate risk and maintain the highest level of compliance to the program.
Alex comes to us with an interdisciplinary background in both Law (LLB) and Pharmaceutical Science (BPcolTox), which allows him to not only interpret your clinical activities with a scientific understanding but additionally leverage his legal experience to look at things from an out of the box lens.
Alex has previously worked for the Gold Coast Hospital and Health Service in the Governance and Compliance Team, which gives him an added layer of understanding with regard to regulations in the healthcare system – advantageous experience that gives him an extra edge to assist our clients!
During Alex’s time at university, he spent his final year researching CRISPR technology and the disruptive potential of advancements in genetic technology – an area he has a particular interest in further discovering.
Partner
Partner
Renee is our Head of R&D and has spent over 11 years as an R&D Tax Specialist. Renee has worked for global Big 4 professional services firms and has successfully partnered with many large clients.
Prior to life as an R&D Tax Specialist, Renee obtained her PhD and had a successful scientific research career in Biotechnology & Bioinformatics. Renee’s blended career experience provides her with a deep insight and understanding of R&D technical concepts to assist companies to identify eligible R&D activities and allows her to bring a strong commercial approach to the R&D claim process.
Renee has led large engagement teams to assist companies (including large multinationals) to access benefits as a result of their R&D initiatives and has worked closely with companies on R&D Tax governance and risk management frameworks. Renee has extensive experience in liaising with regulators in response to the certification of eligible R&D activities, risk reviews and statutory audits.
As part of her role at ABA Bioscience, Renee helps simplify complex reporting and claims processes for clients, allowing them to benefit from their claimable expenditure and ultimately invest more money back into their business. From assessing eligibility requirements and reviewing R&D expenditure to reporting on activities and lodging your application, Renee is your go-to for everything related to the R&D Tax Incentive.
International Client Manager
International Client Manager
Kate is an exceptional strategic account relationship professional, backed by an impressive track record of over 20 years of client management and administrative experience. Her expertise extends across diverse industries, encompassing small-scale enterprises as well as multinational organisations. With a proven ability to foster and nurture relationships, Kate consistently delivers outstanding results for her clients. Her main focus is to oversee, manage and complete the day-to-day operations required of our Bioscience client portfolio and specialised team. Acting as the conduit between our international clients and our internal and external team of specialists, Kate ensures all governance, compliance and other tasks associated with client business operations are strategically considered and taken care of as a matter of priority.
Contract Director
Contract Director
As a pharmaceutical executive and advisor, and experienced investor, Nicoletta contributes to board performance through analytical and strategic thinking, an innovation mindset, and financial acumen. Her expertise ranges from product development to manufacturing, government relations and commercialization through a career with organisations including Kendle and Mayne Pharma (now Pfizer).
An experienced investor and a graduate of the Wade Institute VC Catalyst Program, Nicoletta routinely participates in capital raisings of listed and start-up companies and supports innovation as an adviser to entrepreneurs in the life sciences and health-tech through Spingboard Enterprises (SBE) and the Aging Decelerator.
Nicoletta is committed to continuing education and has recently completed the Women on Boards WOBSX course, a director-led peer to peer support program to assist women achieve ASX board roles and a mentoring program offered by the Victorian Healthcare Association (VHA).
Bioscience Consultant
Bioscience Consultant
Kamand is our Bioscience Consultant who assists the day-to-day operations required of our specialised Bioscience clients and team.
Drawing upon her extensive background in law and conveyancing, Kamand ensures all governance, compliance and other tasks associated with client business operations are strategically considered and taken care of – so you can focus on what matters most.
Kamand is passionate about languages, immersing herself in other cultures and working with clients from all over the globe.
Serotonin Development Assistant
Serotonin Development Assistant
Early mornings at the office can be ruff stuff but rest assured that Tully will greet you at the door with her tail wagging.
As our Chief Wellness Officer, Tully roams the office offering complimentary pats and cuddles, maintaining ultimate serotonin levels for all staff.
Tully takes her role very seriously but her true happiness lies in one word… Chicken.
Contract Director
Contract Director
Kim has over 16 years’ experience in the clinical research field and is the founder of SAPRO Consulting Pty Ltd following her career at a leading Clinical Research Organisation (CRO). Kim has worked with a diverse range of clients including emerging biotech companies, competently guiding and managing global and full service Phase I-IV clinical drug and device studies across many different therapeutic areas. Kim has extensive experience and a proven track record for delivering and executing regulatory strategies within budget and on time whilst proactively negating risk and reporting to board members.
Kim is a certified member of the Regulatory Affairs Professional Society (RAPS) and of the Project Management institute (PMI). Kim has been an invited speaker to present at the ARCS Annual Conference 2019, Sydney – “Challenges of Conducting Phase I Oncology studies in Non-Phase I Units” and most recently invited as an Expert Panel Presenter at Endpoints News Webinar – “Managing Global Studies with Regional Partners” in October 2020.
Kim is originally from Scotland however has spent over 14 years based in Australia which has been crucial to developing and growing clinical trials across the Asia Pacific region. Kim has strong leadership skills and confident decision-making abilities; she thrives within a fast-paced environment and throws herself into new challenges.
Operations / Finance Assistant
Operations / Finance Assistant
Associate
Associate
Kurt is ABA Bioscience’s specialist Legal Consultant. With over 7 years of corporate law firm experience, Kurt understands the demands of companies at each stage in their commercialisation lifecycle and is committed to assisting our clients achieve their true potential.
As a qualified legal practitioner, Kurt holds a Bachelor of Laws and a Graduate Diploma of Legal Practice. However, Kurt’s commitment to perpetual learning and development has driven him to undertake a Bachelor of Biomedical Science. Kurt is passionate about the BioScience industry and is particularly focussed on the intersection of emerging technology and associated legal principles.
Kurt is dedicated to delivering a legal service offering that provides companies with an adequate compliance framework and strategies to protect their emerging technology. In Kurt’s previous role, he gained direct corporate law experience working with clients across the Bioscience sector, where he has prepared various corporate documents such as: shareholders’ agreements, management agreements, IP license agreements, and loan agreements, among other things.
Kurt’s extensive corporate legal experience combined with his bourgeoning knowledge of Bioscience and emerging technologies primes him to deliver a truly unique and valuable service offering to ABA’s Bioscience clients.
Contract Director
Contract Director
Gregor Rozenberg has more than 20 years of international financial and business management experience. He has managed companies as a venture capital investor and chief executive of clinical drug and device companies for the past decade.
Prior to that, he successfully commercialised clean-tech and biotech companies in the UK and held academic positions at both Imperial College London and the University of Cambridge, UK. He is a graduate member of the Australian Institute of Company Directors and his Board experience as a Chair, Director and Observer include more than 20 Australian, UK and US-based life science companies.
More recently, Gregor has been an advisor to a US-based healthcare investment bank and therapeutics-focused private equity and institutional hedge banking firms.
Contract Director
Contract Director
Gerry is an experienced company director, audit and risk committee chair/member and senior corporate executive with expertise in financial, strategic, governance, management and resource areas. He is also the owner and director of a consulting, mentoring and coaching company.
Throughout his corporate career, Gerry has been responsible for maintaining and enhancing external corporate relationships with stockbrokers, analysts, financiers and shareholders. He has also been the key executive driving strategic and business planning processes.
My Medical Department is an independent medical consultancy providing services to the pharmaceutical industry for the advancement of new therapies. Led by physician Dr Catherine Ludwig, their versatile team of scientists, pharmacists, and industry specialists offers you immediate access to a full array of medical functions tailored to meet your needs.
EDR Accounting and Business Solutions works closely with the ABA Bioscience operations team to assist with every step of your accounting journey. They provide expert and proactive advice, bookkeeping, management reporting, accounting and tax services to ensure that clients a remain compliant to their accounting and taxation obligations in Australia.
Cohort Innovation Space is a co-working facility centrally located in the heart of Gold Coast’s Health and Knowledge Precinct. The space is a launchpad for health and technology startups and a home for innovative thinkers, events and support programs.
Send FX specialise in assisting Australian and International Bioscience companies with their foreign exchange and international payment requirements. As an alternative to the traditional banks, Send FX provide our clients with market leading exchange rates, machine learning technology that delivers secure same day payments between currency accounts and pro-active FX risk management.
Synnch is an online comprehensive toolkit designed to help businesses stay compliant, improve productivity and maximise their R&D tax claims. Synnch may assist your business keep contemporaneous R&D activity records.
Toowoomba and Surat Basin Enterprise (TSBE) is the go-to organisation linking business with opportunity to create sustainable growth and diversity for the region. They’re committed to ensuring that the local business community will innovate, adapt and prosper and take pride in encouraging major investment and promoting the vital need for new and upgraded infrastructure in the region.
Director & Founder
Director & Founder
Andrew is the Director and Founder of ABA Bioscience Consulting, ABA Legal Group and an R&D Tax Incentive compliance tool called Synnch, bringing with him a world of experience and ambition for his clients.
Born in Canada, and having worked all around the world, Andrew has a wealth of experience guiding multinational corporations through the complexities of global business. Throughout everything he does, Andrew exudes passion and ambition, and loves being part of the success journey of others.
Andrew is a trusted director and advisor to multiple companies in the Biotechnology, Bioscience, Medtech, BioPharmaceuticals, Life Sciences and AgTech spaces. Through holding these positions, Andrew has also developed a broad network of directors in similar fields.
Andrews is a specialist in the R&D Tax Incentive department where he aims to deconstruct the process in order for clients to maximise their returns, increase business compliance, mitigate risk and importantly, accelerate commercialisation and profitability.
Furthermore, Andrew has extensive experience and a proven track record for guiding and delivering strategic planning to clients through proof of concepts, scaling up, expanding globally and successfully exiting through trade sales, initial public offerings, management buy outs and staged acquisitions from private equity and venture capital funds.